SGLT2 Inhibitors (Gliflozins) Lawsuit Settlements

Parker Waichman LLP Discusses the Recent SGLT2 Inhibitors (Gliflozins) Lawsuit Settlement News

Sodium-Glucose Cotransporter-2 inhibitors (SGLT2) are widely used diabetes drugs. These drugs are known by their brand names such as Invokana, Farxiga, and Jardiance. The clinical names for the SGLT2 medications are canagliflozin, dapagliflozin, and empagliflozin, and sometimes they are combined with other type 2 diabetes treatment drugs such as metformin or linagliptin. SGLT2 medicines have come under heavy scrutiny recently because of their link to many severe and even catastrophic injuries.

Consequently, injured plaintiffs have filed hundreds of lawsuits across the country claiming damages from drug manufacturers like Johnson & Johnson, Janssen Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, and the like. These large and powerful drug companies placed profit over safety by failing to adequately examine the potentially dangerous side effects their powerful drugs could cause. Now, they stand to lose billions of dollars if juries find them liable for the damages these drugs have caused. As a result, the drug companies may settle these lawsuits.

Parker Waichman LLP Fights for Victims of Defective Gliflozin Drugs

You may be entitled to receive financial compensation if you or your loved one has suffered a catastrophic loss such as an amputation of a leg, foot, or toe, or other potentially catastrophic injuries like kidney damage and diabetic ketoacidosis from taking an SGLT2 inhibitor drug. The SGLT2 lawyers from Parker Waichman LLP have extensive experience litigating drug defect cases. Parker Waichman LLP is an experienced national law firm that has successfully brought claims on behalf of numerous people who have suffered at the hands of large drug manufacturers.

These are complex cases. Parker Waichman’s SGLT2 lawyers have the expertise and drive necessary to take on these massive conglomerate corporations and their relentless company lawyers. Parker Waichman’s drug defect lawyers are the advocates you need to make the difference for you. Call us today at 1-800-YOURLAWYER (1-800-968-7529) or fill out our online contact form to discuss your claim with our complex litigation attorneys.

SGLT2 Inhibitor (Gliflozin) Settlements

At this time, there is no information publicly available about SGLT2 settlements. Over 200 cases are pending in the United States District Court for the District of New Jersey. Others are pending in the New Jersey state courts as well. Cases filed in state court include two filed by Parker Waichman LLP in January of 2018. Parker Waichman LLP filed these two lawsuits on behalf of two men who lost limbs due to side effects caused by Invokana, a leading SGLT2 drug manufactured by Janssen Pharmaceuticals and its parent company Johnson & Johnson.

The United States District Court in New Jersey has consolidated the 200 cases pending there using a legal mechanism called “Multi-district Litigation” or “MDL.” The court refers to these consolidated MDL cases not by any one person’s name, as in a typical lawsuit or a class action lawsuit, but by a number. In this instance, the case is called Invokana MDL 2750. The docket for Invokana MDL 2750 reveals that the judges presiding over the MDL regularly hear from the parties, and have frequent court dates to stay on top of the progress of the case as it winds from the pleading stages to the discovery stages, and eventually to the trial stage.

Invokana MDL 2750 has not been ongoing for that long. Therefore, discussion of concrete settlement terms may not be in process at this time. However, most judges make a point of discussing settlement and engaging the parties’ attorneys in negotiations to try to resolve the case at multiple points in the course of a litigation. Of course, each party is entitled to hold their respective ground.

MDL is unlike other cases. The lawyers, in negotiation with each other, and in consultation with the trial judge, will establish what are known as “bellwether” cases as the first cases that will go to trial. Bellwether trials typically represent a cross-section of the litigants and proceed to trial before all other cases in the same MDL.

The benefits of bellwether trials are evident. Each party gets to evaluate the relative merit of their claims based on how the first juries rule in the bellwether trials. Additionally, settlement talks can ramp up after the defendant loses a bellwether trial or two because, by that point, the defendant might realize that they could stand to lose a tremendous amount of money, billions upon billions of dollars, in judgments. In that situation, defendants often realize that the better business practice would be to resolve the matter with a global settlement.

Settlements may be structured in a way to cover the costs of the litigation and attorneys’ fees without taking too much away from the damages each plaintiff could receive. Each plaintiff in the MDL might not receive the same amount of damages. The sum they receive depends on the nature of their injuries and the losses he or she suffered.

You can be sure that Parker Waichman LLP will keep their clients up-to-date at every stage of the litigation, and with any developments that may take place in SGLT2 negotiations that become public.

What Can a Parker Waichman LLP Attorney Do for Me?

Drug defect cases involve very complex issues of liability and causation, and the plaintiffs have the burden to prove that the defendants’ medication caused the damage they suffered. Plaintiffs also must prove that the defendants are liable for the damage by showing that the defendants failed to warn their potential customers about the dangers of their drug and the possible side effects of the drugs.

Issues of liability and causation are much more complicated than showing that the plaintiff took the defendant’s medication and got sick. While that is a necessary part of it, it is only a small piece of the puzzle. The bulk of the proof comes from expert testimony. Medical experts must testify as to what the drug does and how it interacted with the human body and resulted in the damages the plaintiffs suffered. Other experts like pharmaceutical experts and financial experts like economists and actuaries will testify to prove the extent of the economic loss the victim suffered.

These complex issues can only be handled successfully by lawyers who have had significant experience in drug defect litigation. Our diabetes drug attorneys have both the experience and the passion to vigorously pursue the financial compensation to which you are legally entitled. For additional information about SGLT2 drugs visit our Invokana Lawsuits page.

Contact Parker Waichman LLP Today to Discuss Your Gliflozin Amputation Claim

At Parker Waichman LLP, our SGLT2 drug defect attorneys enjoy a reputation as zealous advocates for their clients. If you or your family member sustained a severe injury or amputation of a leg, foot or toe from taking an SGLT2 drug, call Parker Waichman LLP today at 1-800-YOURLAWYER (1-800-968-7529) or use our contact form.

Our law firm has received numerous awards and accolades for quality legal work. Parker Waichman LLP has also obtained over $2 Billion in recoveries for their clients. Please visit our Client Testimonials and Verdicts and Settlements pages for further information about our happy clients and the successes we had on their behalf.